| CRISPR THERAPEUTICS |
| Schweiz |
| Gesundheit |
| CH0334081137 / A2AT0Z |
| 1CG (Frankfurt) / CRSP (NASDAQ) |
| FRA:1CG, ETR:1CG, 1CG:GR, NASDAQ:CRSP |
| - |
| https://crisprtx.com/ |
|
CRISPR Therapeutics AG is a Swiss biotechnology company focused on gene editing and the development of CRISPR/Cas9-based medicines for serious human diseases. Its research and therapeutic portfolio spans areas such as hemoglobinopathies, oncology, re..
>Volltext.. |
| 4432.37 Mio. EUR |
| 3050.32 Mio. EUR |
| 11.92 Mio. EUR |
| -456.61 Mio. EUR |
| -401.4 Mio. EUR |
| -4.24 EUR |
| 697.34 Mio. EUR |
| 259.55 Mio. EUR |
| -328.83 Mio. EUR |
| 17.79 |
| -63.7% |
| 0.53% |
| - |
| - |
| - |
| 4 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 2.224.675 Euro. |
| CRISPR THERAPEUTICS |
| 17.10.26 |
|